2005 Press Releases Communiqués de presse

October 11, 2005 11 October, 2005

Pheromone Sciences to Finance and Acquire Sertonex/Sertoli Technologies

June 8, 2005 8 June, 2005

Pheromone Sciences Appoints New CFO

June 8, 2005 8 June, 2005

Pheromone Sciences Appoints New CFO

March 28, 2005 28 March, 2005

Pheromone Sciences Corp Announces Appointment of Mr. Dev Randhawa, MBA, as President and CEO & Director.

March 14, 2005 14 March, 2005

*Pheromone Sciences Corp Announces USA Launch of Fertility Monitor

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 11, 2005 11 October, 2005

Pheromone Sciences to Finance and Acquire Sertonex/Sertoli Technologies


Kelowna, B.C. and London, Ontario - Pheromone Sciences Corp. ("Pheromone") is pleased to announce today that it has entered into a letter of intent to finance and acquire an interest in Sertonex Inc. ("Sertonex"), a private, London, Ontario-based company engaged in the development and commercialization of biological therapeutics focused on overcoming transplantation rejection. Initially, the technology will be developed for the treatment of insulin- dependent diabetes by co-transplanting Sertoli cells with islets.

Pheromone expects to enter into a financing and option agreement under which Pheromone will have the exclusive right to acquire, in stages, the outstanding securities of Sertonex. Upon closing, Pheromone will issue 2,315,000 common shares in exchange for one third of the issued shares of Sertonex and provide initial project financing of $1.5 million.

Sertonex will sign a licensing agreement with Sertoli Technologies Inc. ("Sertoli"), a privately held company headquartered in Tucson, Arizona, USA, which owns the exclusive worldwide rights to a number of patents and patent applications for the therapeutic use of Sertoli cell technology. Sertoli will exclusively license to Sertonex all patents, patent applications, know-how and intellectual property owned by or licensed to Sertoli in exchange for certain future royalty payments, the issuance of 6,527,500 Pheromone common shares and a cash payment nine months after closing of $1,142,312.

Pheromone will provide up to $3.5 million to support the ongoing pre-clinical trials of the Sertonex/Sertoli technology over the next two years. The initial financing will be raised through a non-brokered private placement of up to $2 million based on units at $0.20 per unit; each unit consisting of one share and one-half a warrant to purchase an additional share at $0.25 for two years. A finder's fee of 7% will be paid and Pheromone will reserve the right to force the exercise of the warrants if the stock trades at a 10-day moving average above $0.50 per share. The closing date for initial financing will be not more than 90 days after approval of the transaction.

Completion of the transaction is subject to a number of conditions, including but not limited to acceptance by the TSX Venture Exchange. There can be no assurance that the transaction will be completed as proposed or at all.

About Sertonex

Sertonex Inc. was incorporated March 2004 in the province of Ontario, Canada, and is operated out of the city of London. Using a portfolio of more than 20 patents for the therapeutic use of Sertoli cell technology (licensed through Sertoli Technologies Inc.), Sertonex is planning to develop an FDA-licensed product to treat insulin- dependent diabetes patients. Sertonex plans to build on the numerous studies completed by Sertoli and its collaborators with the ultimate goal to gain regulatory approval in North American, European and Japanese markets.

Sertonex technology is based on the Sertoli cells' natural ability to locally modulate the immune system. The creation of an immunologically privileged site by Sertoli cells overcomes a major obstacle to routine cell transplantation by removing the need for immunosuppressive drugs. The use of Sertoli cells may enable xenotransplantation (e.g. transplantation from animal to human) and make widespread usage of cell therapy a reality.

About Sertoli

Sertoli Technologies Inc. (STI) is a cellular therapy company with platform technology for creating a local immunoprivileged site enabling the therapeutic transplantation of cells and cell-based gene therapy. STI has a comprehensive patent portfolio covering the application of Sertoli cells. Patent applications are filed worldwide in all major markets, including the United States, Europe and Japan. Six U.S. patents have issued from the seminal work of Dr. Helena Selawry, formerly of the University of Tennessee Medical Center and VA Medical Center in Memphis, containing broad claims that protect the use and application of the Company's technology. The Company is aggressive in filing additional patents covering additional therapeutic uses of Sertoli cells and factors derived from Sertoli cells.

Additional Information on Sertoli is available on its website at www.sertoli.com.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing medical technologies.

The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, President

For further information contact:

Mr. Dev Randhawa Pheromone Sciences Corp. TEL: (250) 868-8177 FAX: (250) 868-8493

Mr. Justin Leushner Sertonex Inc. TEL: (519) 639-7867 FAX: (519) 858-5142

Ms. Jan McCoy Hutchinson Sertoli Technologies Inc. TEL: (520) 748-4458 FAX: (520) 748-0025

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 08, 2005 8 June, 2005

Pheromone Sciences Appoints New CFO


Kelowna, British Columbia - June 8, 2005 - Further to the Company's search for new opportunities to sustain ongoing operation and business development, the Company is pleased to announce that Mr. Patrick Groening has agreed to be the Chief Financial Officer of the Company. Mr. Groening obtained his Chartered Accountant designation in 1999 and is a member of the Institute of Chartered Accountants of British Columbia. He also holds a professional accounting designation as a Certified Public Accountant and is member of the Illinois Board of Examiners in the United States. In addition to being an auditor for several years, Mr. Groening has provided business advisory, information technology, and financial accounting services to many medium and large size organizations.

Mr. Groening is a replacement for Mr. Florian Meyer who the Company thanks for his involvement and contribution in the past.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, President

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward -looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 08, 2005 8 June, 2005

Pheromone Sciences Appoints New CFO


Kelowna, British Columbia - June 8, 2005 - Further to the Company's search for new opportunities to sustain ongoing operation and business development, the Company is pleased to announce that Mr. Patrick Groening has agreed to be the Chief Financial Officer of the Company. Mr. Groening obtained his Chartered Accountant designation in 1999 and is a member of the Institute of Chartered Accountants of British Columbia. He also holds a professional accounting designation as a Certified Public Accountant and is member of the Illinois Board of Examiners in the United States. In addition to being an auditor for several years, Mr. Groening has provided business advisory, information technology, and financial accounting services to many medium and large size organizations.

Mr. Groening is a replacement for Mr. Florian Meyer who the Company thanks for his involvement and contribution in the past.

ON BEHALF OF THE BOARD

"Dev Randhawa"

Dev Randhawa, President

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward -looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 28, 2005 28 March, 2005

Pheromone Sciences Corp Announces Appointment of Mr. Dev Randhawa, MBA, as President and CEO & Director.


Toronto, Ontario - March 28, 2005: Pheromone Sciences Corp. (TSX-V:PHS) today announced that Mr. Dev Randhawa MBA, President and CEO of Strathmore Minerals and a past director of Medicure, will assume the position of President and CEO of the company. Mr. Randhawa will also join the Board of Pheromone Sciences.

Dr. William Cochrane, Chairman of Pheromone Sciences stated, "We are fortunate that Mr. Christopher Newman, the former President and CEO of the company has agreed to remain on the board of Pheromone Sciences Corp. to assure an orderly transition. We thank Mr. Newman for all his hard work and contribution to the development of the company and its technology and are happy that he will continue to provide input based upon his many years of healthcare experience."

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

144 Front Street West, Suite 360 Toronto , Ontario, Canada M5J 2L7 Tel: (416) 861-9854 Fax: (416) 861-9950

INVESTOR CONTACT William Cochrane (403) 270-2438 investor@pheromonesciences.com

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 14, 2005 14 March, 2005

*Pheromone Sciences Corp Announces USA Launch of Fertility Monitor


Toronto, Ontario - March 14, 2005: Pheromone Sciences Corp. (TSX-V:PHS) today announced that HealthWatchSystems Inc. has launched the OV Watch(tm) product in selected markets in the USA. The OV Watch(tm) fertility monitor is a watch like fertility cycle monitoring device, designed and developed by Pheromone Sciences, for the consumer and professional medical market. The OV Watch(tm) looks to set a new benchmark in providing a reliable "predictive" approach to natural, cycle-based family planning through the measurement of perspiration ion changes on the surface of the skin. These changes in female perspiration allow for the prediction of ovulation up to 4 days prior to the day of ovulation without the need for inconvenient urine or blood testing. This advance notice can significantly improve a women's probability of success in conceiving a child.

The OV-Watch(tm) will be competing in a marketplace that is estimated to be valued at US $500 million in America alone. Pheromone Sciences Corporation will receive a stream of royalties based upon the worldwide sales generated by HealthWatchSystems Inc.

More information can be found on both the OV Watch(tm) and HealthWatchSystems Inc. at the website www.ovwatch.com

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company currently seeking new product and technology development opportunities.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.